Cita APA (7a ed.)
Jin, Z., Zhong, B., Chen, J., Zhu, H., Sun, J., Yin, G., . . . Teng, G. (2023). Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): A propensity score matching study. European Radiology, 33(12), 8669-8682.
Cita Chicago Style (17a ed.)
Jin, Zhi-Cheng, et al. "Real-world Efficacy and Safety of TACE Plus Camrelizumab and Apatinib in Patients with HCC (CHANCE2211): A Propensity Score Matching Study." European Radiology 33, no. 12 (2023): 8669-8682.
Cita MLA (9a ed.)
Jin, Zhi-Cheng, et al. "Real-world Efficacy and Safety of TACE Plus Camrelizumab and Apatinib in Patients with HCC (CHANCE2211): A Propensity Score Matching Study." European Radiology, vol. 33, no. 12, 2023, pp. 8669-8682.
Precaución: Estas citas no son 100% exactas.